Tag: ACT Eye Trials Begin Dosing Third Patient

Advanced Cell Technology, Inc. (ACT) has announced it is dosing its third patient in a clinical study which utilizes retinal pigment epithelial (RPE) cells taken from human embryonic stem cells (hESCs) to find a treatment for dry age-related macular degeneration (AMD). The study, currently in its Phase I/II trial stage, began on Jan. 20 of […]